Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QihaPingchuan Capsule is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of respiratory conditions such as bronchial asthma and chronic bronchitis. The product is designed to tonify the lungs and kidneys, resolve phlegm, and suppress cough and wheezing. Its composition typically includes a blend of herbal and animal-derived ingredients, most notably *Astragalus membranaceus* (Huangqi), *Gecko* (Gejie), and *Ephedra sinica* (Mahuang). The therapeutic efficacy of the capsule is attributed to the synergistic effects of its components, which provide anti-inflammatory, bronchodilatory, and immunomodulatory activities. Specifically, the presence of ephedrine alkaloids from *Ephedra* contributes to airway relaxation, while other constituents modulate inflammatory cytokine pathways to reduce bronchial hyperresponsiveness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QihaPingchuan Capsule.